具体情况如下： 一、药品情况 （一） 信超妥 1、 基本情况 药品名称：沙库巴曲阿利沙坦钙片 医保类别：乙类 证券代码：002294 证券简称：信立泰 编号：2025-061 深圳信立泰药业股份有限公司 关于信超妥、复立安® 、恩那罗®等药品 纳入国家医保目录的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 根据国家医保局、人力资源社会保障部发布的《关于印发〈国家基本医疗保 险、生育保险和工伤保险药品目录〉以及〈商业健康保险创新药品目录〉（2025 年）的通知》（医保发〔2025〕33 号）（下称"《通知》"），深圳信立泰药 业股份有限公司（下称"公司"）的药品信超妥（沙库巴曲阿利沙坦钙片）、复 立安®（阿利沙坦酯吲达帕胺缓释片），通过谈判新纳入《国家基本医疗保险、 生育保险和工伤保险药品目录（2025 年）》（下称"医保目录"）乙类范围， 恩那罗®（恩那度司他片）续约成功保留在医保目录内；信立坦（阿利沙坦酯片） 调整至医保常规目录管理。 备注：限原发性高血压。 协议有效期：2026 年 1 月 1 日至 2027 年 12 月 31 日。 信超妥本次为 ...

证券之星消息，12月4日，生物经济（970038）指数报收于2117.66点，跌0.2%，成交104.77亿元，换手 率0.98%。当日该指数成份股中，上涨的有17家，信立泰以3.4%的涨幅领涨，下跌的有33家，华兰疫苗 以5.75%的跌幅领跌。 近10日内生物经济（970038）指数成份股做了调整，新纳入了9只股票，剔除了9只股票。 资金流向方面，生物经济（970038）指数成份股当日主力资金净流出合计4.59亿元，游资资金净流入合 计3157.72万元，散户资金净流入合计4.28亿元。成份股资金流向详情见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300026 红日药业 | | 3806.67万 | 7.20% | 2160.87万 | 4.09% | -5967.54万 | -11.29% | | 002019 亿帆医药 | | 2587.00万 | 11.47% | -274.72万 | -1.2 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 二〇二五年十二月四日 （详见2025年2月14日、2025年4月29日、2025年8月29日、2025年9月30日登载于信息披露媒体《中国证 券报》、《证券时报》、巨潮资讯网www.cninfo.com.cn的《关于SAL0140药品临床试验申请获得受理的 公告》、《关于SAL0140获得临床试验批准通知书的公告》） SAL0140若能研发成功并获批上市，将有望为更多细分领域的患者有针对性地提供新的用药选择，满足 未被满足的临床需求，并进一步丰富公司慢病领域的创新产品管线。 公司将按国家药品注册的相关规定和要求开展临床试验，待临床试验成功后按程序注册申报。根据普遍 的行业特点，药品研发周期长、风险较高，从临床到上市受到多方面因素影响，存在不确定性，短期内 对公司业绩不会产生实际影响。公司将按规定对有关后续进展情况及时履行信息披露义务，敬请广大投 资者理性投资，注意风险。 特此公告 深圳信立泰药业股份有限公司 董事会 近日，深圳信立泰药业股份有限公司（下称"公司"） ...

今日（12.4），港药四连跌后强势反弹，创新药纯度100%的港股通创新药ETF(159570)四连跌后首次反弹涨1.5%，成交额快速突破12亿元！资金面上，此前 三日连续回调吸金，近5日累计净流入超1.8亿元！截至12月3日，港股通创新药ETF(159570)最新规模超232亿元，同类持续领先！ 消息面上，12月3日，信立泰发布公告，公司收到药监局核准签发的《临床试验批准通知书》，同意公司自主研发的创新小分子药物SAL0140片开展治疗慢 性肾脏病（CKD）的临床试验。 港股通创新药ETF(159570)标的指数权重股多数飘红：康方生物、科伦博泰生物-B、金斯瑞生物科技涨超3%，信达生物涨超2%，百济神州涨近2%，三生制 药涨近1%，中国生物制药微涨。 | 序号 | 代码 | 名称 | 估算权重 | 涨跌幅 | 成交额 | | --- | --- | --- | --- | --- | --- | | 1 | 6160 | 百济神州 | 11.90% | 2.19% | 2.99亿 | | 2 | 1801 | 信达生物 | 11.38% | 2.02% | 2.28亿 | | 3 | 9926 | 康方生物 ...

Group 1 - Guizhou BaiLing's actual controller Jiang Wei has been investigated by the China Securities Regulatory Commission (CSRC) for insider trading and information disclosure violations [1] - The investigation highlights the regulatory focus on key individuals and may increase operational uncertainty for Guizhou BaiLing, which has faced performance pressures in recent years [1] - The CSRC's actions reflect ongoing efforts to enhance the rule of law in the capital market [1] Group 2 - Jianyou Co., Ltd. has received ANDA approval from the FDA for its Propofol emulsion injection, marking a significant step in the company's internationalization of its formulations [2] - The product is expected to have a broad market potential in the U.S. as a commonly used sedative for surgeries, potentially driving revenue growth for the company [2] Group 3 - Shenzhen Xinlitai has been granted clinical trial approval for its innovative small molecule drug SAL0140, aimed at treating chronic kidney disease (CKD) [3] - SAL0140 is a proprietary aldosterone synthase inhibitor with potential applications in multiple significant chronic disease areas, indicating substantial market potential [3] - Successful development could open new growth avenues for Shenzhen Xinlitai [3] Group 4 - Junshi Biosciences reported a decrease in the shareholding percentage of Greenland Financial Investment Group and its affiliates from 5.0051% to 4.7129% due to share lending [4] - This change is a technical operation rather than an active reduction in holdings, but it brings the shareholding below the 5% disclosure threshold, warranting market attention on future actions [4] Group 5 - Sichuan Sichuang Medical Technology Co., Ltd. announced the resignation of Chairman Xu Yiran to facilitate governance structure optimization, while he will remain a board member [5] - The appointment of Wei Naixu as the new chairman indicates a strategic move to clarify responsibilities and strengthen governance rather than a response to a crisis [5]

Group 1 - Guizhou BaiLing's actual controller Jiang Wei has been investigated by the China Securities Regulatory Commission (CSRC) for insider trading and information disclosure violations, indicating a focus on regulatory enforcement against key individuals [1] - The investigation may exacerbate operational uncertainties for Guizhou BaiLing, which has faced performance pressures in recent years, raising concerns about corporate governance and information disclosure risks [1] Group 2 - Jianyou Co., Ltd. has received ANDA approval from the FDA for its propofol emulsion injection, marking a significant step in the company's internationalization of its formulations [2] - The product, commonly used for sedation during surgeries, has substantial market potential in the U.S., which is expected to contribute to revenue growth for Jianyou [2] Group 3 - Shenzhen Xinlitai Pharmaceutical Co., Ltd. has been granted clinical trial approval for its innovative small molecule drug SAL0140, aimed at treating chronic kidney disease (CKD) [3] - SAL0140, an aldosterone synthase inhibitor, targets multiple significant chronic disease areas, including uncontrolled hypertension and CKD, presenting considerable market potential for the company [3] Group 4 - Junshi Biosciences reported a decrease in the shareholding percentage of Greenland Financial Investment Group and its affiliates from 5.0051% to 4.7129% due to share lending, falling below the 5% disclosure threshold [4] - This change is primarily a technical operation rather than an active reduction in holdings, but the market will need to monitor the future actions of these shareholders [4] Group 5 - Sichuang Medical Technology has elected Wei Naixu as the new chairman following the resignation of Xu Yiran, who stepped down to facilitate governance structure optimization [5] - Xu Yiran will remain on the board, indicating that the adjustment aims to clarify responsibilities and strengthen governance rather than signaling a crisis [5]

Core Viewpoint - The company, Xinlitai (002294.SZ), has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0140, aimed at treating chronic kidney disease (CKD) [1] Group 1: Drug Development - SAL0140 is a proprietary aldosterone synthase inhibitor developed by the company, targeting conditions such as uncontrolled hypertension (including resistant hypertension), primary aldosteronism, and chronic kidney disease (CKD) [1] - The drug is expected to mitigate end-organ damage through the inhibition of aldosterone synthesis, potentially improving the progression of chronic kidney disease [1] Group 2: Mechanism of Action - Aldosterone is a crucial mineralocorticoid hormone that maintains fluid and electrolyte balance by activating mineralocorticoid receptors (MR), and it is directly involved in various cardiovascular and renal diseases [1] - Aldosterone synthase inhibitors may offer therapeutic benefits by reducing both genomic and non-genomic effects associated with end-organ damage [1]

Core Viewpoint - The company, Xinlitai (002294.SZ), has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0140, aimed at treating chronic kidney disease (CKD) [1] Group 1: Drug Development - SAL0140 is a proprietary aldosterone synthase inhibitor developed by the company, targeting indications such as uncontrolled hypertension (including resistant hypertension), primary aldosteronism, and chronic kidney disease (CKD) [1] - The drug aims to inhibit the synthesis of aldosterone, which is crucial for maintaining fluid and electrolyte balance, and is involved in various cardiovascular and renal diseases [1] Group 2: Mechanism of Action - Aldosterone is the most important mineralocorticoid hormone in the human body, activating mineralocorticoid receptors (MR) to regulate fluid and electrolyte balance [1] - Aldosterone synthase inhibitors are expected to mitigate end-organ damage caused by both genomic and non-genomic effects, potentially improving the progression of chronic kidney disease [1]

Core Viewpoint - Recently, the company received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0140 for the treatment of chronic kidney disease (CKD) [1] Group 1: Company Developments - The company announced that SAL0140 is a proprietary aldosterone synthase inhibitor [1] - The drug is intended to target indications including uncontrolled hypertension (including resistant hypertension), primary hyperaldosteronism, and chronic kidney disease (CKD) [1]

醛固酮是人体最重要的盐皮质激素，通过激活盐皮质激素受体（MR）来维 持体液和电解质的平衡，同时直接参与多种心血管和肾脏疾病的靶器官损伤。醛 固酮合酶抑制剂有望通过抑制醛固酮的合成，减轻基因组和非基因组效应下的终 末器官损伤，具有改善慢性肾病进展的潜力。 证券代码：002294 证券简称：信立泰 编号：2025-060 深圳信立泰药业股份有限公司 获得临床试验批准通知书的公告 （详见 2025 年 2 月 14 日、2025 年 4 月 29 日、2025 年 8 月 29 日、2025 年 9 月 30 日 登载于信息披露媒体《中国证券报》、《证券时报》、巨潮资讯网 www.cninfo.com.cn 的《关 于 SAL0140 药品临床试验申请获得受理的公告》、《关于 SAL0140 获得临床试验批准通知 书的公告》） 关于 SAL0140 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，深圳信立泰药业股份有限公司（下称"公司"）收到国家药品监督管 理局核准签发的《临床试验批准通知书》，同意公司自主研发的创新小分子药物 SAL0140 片（项目代码：S ...